Synthon welcomes Anish Mehta to its Board of Directors as CEO

– NETHERLANDS, Nijmegen –  Synthon BV, an international, science-centered pharmaceutical company specialized in developing and manufacturing high-quality generic and hybrid medicines for patients around the world, today announced the appointment of Anish Mehta as CEO and member of the Board of Directors, effective immediately.

“We are delighted to welcome Anish to Synthon. Anish’s successful track record, deep industry expertise and his energetic and result-driven personality will help Synthon to continue delivering on our purpose of developing therapies that improve health and well-being globally”, said Executive Chairman. Hans Stols.

“The appointment of Anish is a really exciting addition to the Executive team at Synthon”, said Mark Hersee, Partner at BC Partners. “Anish brings a wealth of complementary experience to Synthon as we look to invest in, and drive future growth. Having been both a customer of Synthon and competed against its products, Anish has a deep understanding of what is required to take Synthon to the next level of success. We look forward to supporting Anish and the rest of the Synthon team in achieving that goal.”

About Anish Mehta

Anish is a global healthcare veteran with more than 20 years of experience in innovative and generic pharmaceuticals. Before joining Synthon, Anish was the CEO of Theramex, a global specialty pharma company dedicated to Women’s Health, where he established the company following the acquisition and carve out from Teva. Before joining Theramex, Anish worked at Allergan in a variety of strategic, commercial, and business development roles, including general management in Europe, the Middle East, and Africa where he led large teams focused on profitably growing generics businesses through sales effectiveness and portfolio expansion.

“I am honored to be joining Synthon at such an exciting time. I look forward to working with my talented colleagues to accelerate growth and serve our patients and partners around the world with affordable, high-quality generic and hybrid medicines”, said Anish Mehta.

About Synthon

Synthon is an international, science-centered pharmaceutical company specialized in developing, manufacturing, and out-licensing complex high-quality generic and hybrid medicines for patients around the world. Synthon’s innovative R&D and proven ability to manufacture and distribute high-quality pharmaceuticals position the company well for the future. In November 2019, funds advised by BC Partners acquired a majority stake in Synthon International Holding B.V.

For more information: https://www.synthon.com/

- DisclaimerNews, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.